Patricia Inacio, PhD,  science writer—

Cour Pharmaceuticals is launching a Phase 1b/2a proof-of-concept study to evaluate the safety and preliminary effectiveness of its investigational therapy CNP-106, an immune-modifying nanoparticle that’s designed to reprogram the immune system in adults with myasthenia gravis (MG). The announcement follows the U.S. Food and Drug Administration’s (FDA) approval of…

People with myasthenia gravis (MG) who are receiving immunosuppressive therapy are more likely to be hospitalized for a COVID-19 infection, yet the majority of patients are discharged without any complications, a single center study reports. “Immunosuppressive therapy was continued during COVID-19 infection,” and “most of hospitalized patients were discharged…

Long-term immunotherapy may cause anemia in female patients with myasthenia gravis (MG), according to a Japanese study that found that women with this blood condition — one of the potential side effects of immunotherapy — had significantly worse disease severity. Anemia, a condition marked by a low…

Virtis Health announced that it will open two ambulatory centers in Ohio — one in Columbus and the other in Cleveland — for people in need of infusion therapies, including those with myasthenia gravis (MG). Virtis is a division of Soleo Health, a pharmacy specialized in the…

Researchers in Iran reported the first case of myasthenia gravis (MG) following a Sinopharm vaccination against SARS-CoV-2, the virus that causes COVID-19. The report follows evidence of a possible link between COVID-19 vaccination and MG. While the mechanisms remain unclear, “if muscle weakness, ocular and bulbar [neck and facial]…

Researchers in Italy have reported three cases of myasthenia gravis (MG) they say may possibly have been caused by a vaccine against SARS-CoV-2, the virus that causes COVID-19. “Clinicians should be aware of possible new-onset MG after SARS-CoV-2 vaccination, especially with the current recommendation of booster doses,” the team…

Ultomiris (ravulizumab) has been recommended for approval in the European Union (EU) as an add-on therapy for most adults with generalized myasthenia gravis (gMG). The recommendation by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, specifically covers gMG patients who are positive…

Contrary to increasing evidence, high-intensity inpatient rehabilitation was not found, in a Japanese study, to speed the recovery of people with myasthenia gravis (MG) who were intubated after a myasthenic crisis. Instead, according to researchers, “high-intensity rehabilitation was associated with delayed recovery in the ADL [activities of daily living],”…

Soliris (eculizumab) safely and rapidly led to clinical benefits in people with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive, according to data from a small real-world U.S. study. Moreover, most patients discontinued maintenance immunomodulatory treatment. The study, “Safety and outcomes of eculizumab for acetylcholine…

People with myasthenia gravis, particularly women, have a high symptom burden that considerably affects their health-related quality of life, but the disease’s human cost is rarely given adequate study, a systematic literature review has found. Symptoms generally eased following treatment and disease remission. Still, there is…